ATLANTA, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits: Unicycive Therapeutics (UNCY) The shareholder class action lawsuit filed against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts regarding Unicycive’s readiness and ability to satisfy the FDA’ ...

ATLANTA, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC announces that it has filed a shareholder class action lawsuit against Marex, Inc. (“Marex” or the “Company”) (NASDAQ: MRX). The lawsuit alleges that Defendants failed to disclose to investors that: (1) the Company sold over-the-counter financial instruments to itself; (2) Marex had inconsistencies in its financial statements between its subsidiaries and related parties, including as to intercompany receivables and loans; (3) as a result of the ...

ATLANTA, Oct. 08, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Cepton, Inc. (“Cepton” or the “Company”) (NASDAQ: CPTN). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Spirit’s business, operations, and prospects, including allegations that: (i) Cepton had received a credible third-party bid valuing Cepton at more than double the Koito Acquisition; (ii) Cepton's Board ...

ATLANTA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Spirit Aviation Holdings, Inc. (“Spirit” or the “Company”) (NYSE: FLYY). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Spirit’s business, operations, and prospects, including allegations that: (i) Spirit was at substantial risk of being unable to meet certain of its debt and other financial obligations; ...

Group 1 - A shareholder class action lawsuit has been filed against KBR, Inc. alleging that the company made materially false and misleading statements regarding its business operations and prospects [1] - The lawsuit claims that KBR misrepresented the status of its partnership with the U.S. Department of Defense's Transportation Command (TRANSCOM), despite known concerns about HomeSafe's ability to fulfill the Global Household Goods Contract [1] - The period for affected shareholders to seek legal recourse is from May 6, 2025, to June 19, 2025, with a deadline to be appointed lead plaintiff by November 18, 2025 [2] Group 2 - Holzer & Holzer, LLC is representing the shareholders in this litigation and has a history of recovering significant amounts for investors affected by corporate misconduct [2] - The firm has been recognized as an ISS top-rated securities litigation law firm for the years 2021, 2022, and 2023 [2] - Holzer & Holzer, LLC has been active in shareholder class action and derivative litigation since its founding in 2000 [2]

Core Points - A shareholder class action lawsuit has been filed against Jasper Therapeutics, Inc. alleging materially false and misleading statements regarding the company's business and compliance policies [1] - The lawsuit claims that Jasper lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its product briquilimab [1] - The allegations suggest that Jasper's business and financial prospects, as well as briquilimab's clinical and commercial prospects, were overstated [1] Legal Context - Shareholders who purchased Jasper shares between November 30, 2023, and July 3, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request lead plaintiff status in the lawsuit is November 18, 2025 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for investors affected by corporate misconduct [3]

Core Points - A shareholder class action lawsuit has been filed against Quanex Building Products Corporation alleging materially false and misleading statements regarding the company's business and operations [1] - The lawsuit claims that Quanex's tooling and equipment maintenance procedures in its Tyman, Mexico facility were significantly underinvested, leading to degraded conditions [1] - It is alleged that these issues will result in significant costs and delay the expected benefits from the Tyman integration [1] - The company had previously identified these issues but failed to disclose them [1] Legal Information - Shareholders who purchased Quanex shares between December 12, 2024, and September 5, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request to be appointed lead plaintiff in the case is November 18, 2025 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for investors [3]

Core Points - A shareholder class action lawsuit has been filed against Cytokinetics, alleging that the company misrepresented its expectations for FDA approval of aficamten and failed to disclose material risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS) [1] - The lawsuit claims that Cytokinetics indicated an expectation for FDA approval in the second half of 2025, based on a PDUFA date of September 26, 2025 [1] - The lawsuit is aimed at shareholders who purchased shares between December 27, 2023, and May 6, 2025, and experienced significant losses [2] Legal Information - The deadline for shareholders to request to be appointed as lead plaintiff in the case is November 17, 2025 [3] - Holzer & Holzer, LLC is the law firm representing the shareholders, known for its vigorous representation in securities litigation [3]

Core Points - A shareholder class action lawsuit has been filed against V.F. Corporation (VFC) alleging that the company made materially false and misleading statements regarding its turnaround plan, Reinvent, particularly concerning the Vans brand's revenue growth trajectory [1] - The lawsuit claims that significant reset actions were necessary for the Vans brand to return to growth, which were not disclosed by the defendants [1] Legal Context - Shareholders who purchased VFC shares between October 30, 2023, and May 20, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request to be appointed lead plaintiff in the case is November 12, 2025 [3]

Group 1 - A class action has been filed on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) [1] - The class action pertains to purchases of common stock made during Alto's initial public offering on or about February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [1] - Alto Neuroscience is identified as a clinical-stage biopharmaceutical company based in the U.S. [1]